Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients
- 188 Downloads
Purpose: To characterise the gastrointestinal toxicities associated with Trastuzumab administration in HER2-overexpressing breast cancer patients. Methods: All patients (n = 46) who received Trastuzumab as a single agent or in conjunction with conventional anti-cancer treatment within the Royal Adelaide Hospital Cancer Centre from 2002–2007 were included in this study. A retrospective analysis of case-notes was conducted to investigate the toxicities associated with Trastuzumab. Results: Trastuzumab as a single agent induced toxicities following 22% of administrations. Gastrointestinal toxicities were observed following 12% of administrations and included nausea and vomiting, diarrhoea, abdominal pain and bloating. However, other prominent toxicities that were not related to the gastrointestinal tract were also observed including fatigue and lung symptoms (10.4%). Elderly patients (≥60 years) and those with metastatic disease experienced the highest frequency of toxicity. Conclusion: Trastuzumab induces a range of gastrointestinal toxicities in HER2-overexpressing breast cancer patients. These toxicities are separate to those caused by concurrent chemotherapy and/or radiotherapy.
KeywordsHER2-overexpressing breast cancer Targeted therapy Trastuzumab Gastrointestinal tract Toxicity
Noor Al-Dasooqi was supported by an Honours scholarship from the Royal Adelaide Hospital; Dr. Rachel J Gibson was supported by a Research Fellowship from the Cancer Council South Australia; Dr. Joanne M Bowen was supported by a Research Fellowship from the Royal Adelaide Hospital; Professor Dorothy M. Keefe is the Cancer Council SA Chair of Cancer Medicine.
- 4.Cobleigh MA, Vogel CL, Tripathy D, Robert NJ et al (1999) Multinational study of the efficacy and safety of the humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressinf metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648PubMedGoogle Scholar
- 18.Roche Pharmaceuticals (2006) Herceptin TGA approved product information sheet. Roche Pharmaceuticals, Nutley, NJGoogle Scholar
- 23.Crown JP, Burris HA, Boyle F, Jones S, Koehler M, Newstat BO et al (2008). Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat doi: 10.1007/s10549-007-9860-9
- 26.National Comprehensive Cancer Network (2008) Clinical practice guidelines in clinical oncology. National Comprehensive Cancer Network, Jenkintown, PAGoogle Scholar